Higher rate of long-term serologic response of four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: 4-year follow-up of a randomised controlled trial.
Adult
CD4 Lymphocyte Count
Dose-Response Relationship, Immunologic
Female
Follow-Up Studies
HIV Infections
/ complications
HIV-1
/ immunology
Hepatitis B
/ immunology
Hepatitis B Antibodies
/ blood
Hepatitis B Vaccines
/ administration & dosage
Humans
Immunization Schedule
Immunogenicity, Vaccine
Male
Middle Aged
Vaccines, Synthetic
/ administration & dosage
Four doses
Four double doses
HIV infection
Hepatitis B vaccination
Immunogenicity
Journal
AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921
Informations de publication
Date de publication:
11 11 2019
11 11 2019
Historique:
received:
02
06
2019
accepted:
25
10
2019
entrez:
13
11
2019
pubmed:
13
11
2019
medline:
6
5
2020
Statut:
epublish
Résumé
We previously reported that four doses or four double doses of hepatitis B vaccination regimens could not significantly increase a response rate compared with standard doses. However, the antibody levels were higher in the four doses and four double doses groups. This study followed those patients for at least 3 years and aimed to evaluate the immunogenicity of the three vaccination regimens. HIV-infected adults who had CD4+ cell counts > 200 cells/mm At a median duration of 49.7 months (range 46.7-53.7) after completion of the primary vaccination schedule, the percentages of responders with anti-HBs ≥ 10 mIU/mL were 57.1% (95% CI 41.5-72.8%) in the standard doses group; 76.7% (95% CI 63.6-89.9%) in the four doses group (P = 0.067 vs. the standard doses group); and 80.5% (95% CI 67.8-93.2%) in the four double doses group (P = 0.033 vs. the standard doses group). Factors associated with a responder were the vaccination schedule (either four doses or four double doses groups) and a younger age. Despite the highly effectiveness of the standard hepatitis B vaccination regimen at 6 months after completion, the long-term immunogenicity was lower than the four double doses regimen among HIV-infected adults with CD4+ cell counts > 200 cells/mm
Sections du résumé
BACKGROUND
We previously reported that four doses or four double doses of hepatitis B vaccination regimens could not significantly increase a response rate compared with standard doses. However, the antibody levels were higher in the four doses and four double doses groups. This study followed those patients for at least 3 years and aimed to evaluate the immunogenicity of the three vaccination regimens.
METHODS
HIV-infected adults who had CD4+ cell counts > 200 cells/mm
RESULTS
At a median duration of 49.7 months (range 46.7-53.7) after completion of the primary vaccination schedule, the percentages of responders with anti-HBs ≥ 10 mIU/mL were 57.1% (95% CI 41.5-72.8%) in the standard doses group; 76.7% (95% CI 63.6-89.9%) in the four doses group (P = 0.067 vs. the standard doses group); and 80.5% (95% CI 67.8-93.2%) in the four double doses group (P = 0.033 vs. the standard doses group). Factors associated with a responder were the vaccination schedule (either four doses or four double doses groups) and a younger age.
CONCLUSIONS
Despite the highly effectiveness of the standard hepatitis B vaccination regimen at 6 months after completion, the long-term immunogenicity was lower than the four double doses regimen among HIV-infected adults with CD4+ cell counts > 200 cells/mm
Identifiants
pubmed: 31711528
doi: 10.1186/s12981-019-0249-8
pii: 10.1186/s12981-019-0249-8
pmc: PMC6844022
doi:
Substances chimiques
Hepatitis B Antibodies
0
Hepatitis B Vaccines
0
Vaccines, Synthetic
0
Banques de données
ClinicalTrials.gov
['NCT01289106', 'NCT02713620', 'NCT01289106']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
33Subventions
Organisme : Dean of the Faculty of Arts and Sciences, Dartmouth College (US)
ID : 061/2559
Pays : International
Références
Open Virol J. 2011;5:109-13
pubmed: 22043256
J Infect Dis. 2011 Apr 1;203(7):984-91
pubmed: 21266513
J Infect Dis. 2013 Feb 1;207(3):402-10
pubmed: 23175769
Vaccine. 2009 Jan 1;27(1):17-22
pubmed: 18984022
Vaccine. 2005 Apr 22;23(22):2902-8
pubmed: 15780739
Vaccine. 2013 Feb 4;31(7):1040-4
pubmed: 23273969
Vaccine. 2010 Feb 10;28(6):1447-50
pubmed: 19995540
Vaccine. 2009 Jul 23;27(34):4731-8
pubmed: 19540026
Vaccine. 2016 Apr 12;34(17):2044-50
pubmed: 26685092
AIDS Res Ther. 2006 Apr 06;3:9
pubmed: 16600028
Vaccine. 2012 Sep 7;30(41):5973-7
pubmed: 22828589
Vaccine. 2003 Nov 7;21(31):4545-9
pubmed: 14575766
JAMA Intern Med. 2016 May 1;176(5):603-10
pubmed: 27064975
N Engl J Med. 1986 Jul 24;315(4):209-14
pubmed: 2941687
Scand J Infect Dis. 2008;40(1):54-8
pubmed: 17852939
Vaccine. 2010 Aug 2;28(34):5597-604
pubmed: 20600512
AIDS Res Hum Retroviruses. 2018 Nov;34(11):922-928
pubmed: 29926738
JAMA. 2011 Apr 13;305(14):1432-40
pubmed: 21486976
J Infect. 1986 Jul;13 Suppl A:39-45
pubmed: 2943814
Vaccine. 2017 Jul 24;35(33):4155-4161
pubmed: 28669615
PLoS One. 2013 Nov 12;8(11):e80409
pubmed: 24265819
Vaccine. 2006 Nov 30;24(49-50):7124-8
pubmed: 16884833
Drugs. 2003;63(10):1021-51
pubmed: 12699402